Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients

[1]  C. Ingvar,et al.  Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events , 2014, SpringerPlus.

[2]  M. Uhlén,et al.  HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome , 2014, Diagnostic Pathology.

[3]  J. Gustafsson,et al.  On estrogen, cholesterol metabolism, and breast cancer. , 2014, The New England journal of medicine.

[4]  Jeff S. Jasper,et al.  27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology , 2013, Science.

[5]  J. Manson,et al.  Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[6]  N. Loman,et al.  Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial , 2013, Breast Cancer Research and Treatment.

[7]  C. Ingvar,et al.  Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status , 2013, Cancer Causes & Control.

[8]  J. W. Clendening,et al.  Targeting tumor cell metabolism with statins , 2012, Oncogene.

[9]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[10]  C. Ingvar,et al.  Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort , 2012, Cancer Causes & Control.

[11]  C. Ingvar,et al.  Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort , 2012, Cancer Prevention Research.

[12]  C. Ingvar,et al.  Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients , 2011, British Journal of Cancer.

[13]  R. Millikan,et al.  Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen , 2011, Breast Cancer Research.

[14]  D. Rose,et al.  Interaction between menopausal status and obesity in affecting breast cancer risk. , 2010, Maturitas.

[15]  C. Ingvar,et al.  CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients , 2009, British Journal of Cancer.

[16]  F. Pontén,et al.  Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer , 2008, Breast Cancer Research.

[17]  F. Pontén,et al.  HMG‐CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors , 2008, International journal of cancer.

[18]  L. Esserman,et al.  Estrogen Receptor–Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users , 2008, Cancer Epidemiology Biomarkers & Prevention.

[19]  C. Ingvar,et al.  Coffee Consumption and CYP1A2*1F Genotype Modify Age at Breast Cancer Diagnosis and Estrogen Receptor Status , 2008, Cancer Epidemiology Biomarkers & Prevention.

[20]  D. Miglioretti,et al.  Statin Use and Breast Cancer Risk in a Large Population-Based Setting , 2007, Cancer Epidemiology Biomarkers & Prevention.

[21]  Helena Jernström,et al.  Of cup and bra size: Reply to a prospective study of breast size and premenopausal breast cancer incidence , 2006, International journal of cancer.

[22]  E. Petricoin,et al.  Breast cancer growth prevention by statins. , 2006, Cancer research.

[23]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[24]  A. Józkowicz,et al.  Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. , 2005, Current cancer drug targets.

[25]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[26]  J. Olsen,et al.  Cancer risk among statin users: A population‐based cohort study , 2005, International journal of cancer.

[27]  G. Thorgeirsson,et al.  Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.

[28]  H. Mo,et al.  Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention , 2004, Experimental biology and medicine.

[29]  H Jick,et al.  Statin use and cancer risk in the General Practice Research Database , 2004, British Journal of Cancer.

[30]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[31]  H. Mo,et al.  Isoprenoid-Mediated Inhibition of Mevalonate Synthesis: Potential Application to Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[32]  O. Larsson,et al.  Requirement for mevalonate in the control of proliferation of human breast cancer cells. , 1992, Anticancer research.

[33]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[34]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[35]  A. Trentham-Dietz,et al.  Statin use and risk of breast cancer , 2008, Cancer.